Evidence map›Paper›PMID 36029457›Full record

ArticleInternational journal of hematology2022

Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.

Yoko Edahiro, Kohshi Ohishi, Akihiko Gotoh, Katsuto Takenaka, Hirohiko Shibayama, Takayuki Shimizu, Kensuke Usuki, Kazuya Shimoda, Masafumi Ito, Scott A VanWart and 7 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 2 countries.

Yoko EdahiroDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. yedahiro@juntendo.ac.jp.
Kohshi OhishiDepartment of Transfusion Medicine and Cell Therapy, Mie University Hospital, 2-174 Edobashi, Tsu-shi, Mie, 514-8507, Japan.
Akihiko GotohDepartment of Hematology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Katsuto TakenakaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon-shi, Ehime, 791-0295, Japan.
Hirohiko ShibayamaDepartment of Hematology, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan.
Takayuki ShimizuDivision of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake-cho, Miyazaki-city, Miyazaki, 889-1692, Japan.
Masafumi ItoDepartment of Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya-shi, Aichi, 453-8511, Japan.
Scott A VanWartEnhanced Pharmacodynamics, LLC, 701 Ellicott Street, Buffalo, NY, 14203, USA.
Oleh ZagrijtschukPharmaEssentia USA Corporation, 35 Corporate Drive, Suite 325, Burlington, MA, 01803, USA.
Albert QinPharmaEssentia Corporation, 13F, No. 3, YuanQu Sreet, NanKang District, Taipei, 115, Taiwan.
Hiroaki KawasePharmaEssentia Japan K.K, Akasaka Center Building 12F, 1-3-13 Moto-akasaka, Minato-ku, Tokyo, 107‑0051, Japan.
Narihisa MiyachiPharmaEssentia Japan K.K, Akasaka Center Building 12F, 1-3-13 Moto-akasaka, Minato-ku, Tokyo, 107‑0051, Japan.
Toshiaki SatoPharmaEssentia Japan K.K, Akasaka Center Building 12F, 1-3-13 Moto-akasaka, Minato-ku, Tokyo, 107‑0051, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Keita KiritoDepartment of Hematology and Oncology, University of Yamanashi, 1110 Shimokato, Chuo-shi, Yamanashi, 409-3898, Japan.
EA Pharma (Japan) · JPAngioDynamics (United States) · USEhime University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPJuntendo University · JPKeio University · JPMie University Hospital · JPNTT Medical Center · JPOsaka National Hospital · JPTokyo Medical University · JPUniversity of Miyazaki · JPUniversity of Yamanashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36029457
OpenAlexW4293321950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.